医药行业分析
- (2024-11-14)
- (2024-11-14)
- (2024-11-14)
- (2024-11-14)
- (2024-11-14)
- (2024-11-14)
- (2024-11-13)
- (2024-11-13)
- (2024-11-13)
- (2024-11-13)
- (2024-11-13)
- (2024-11-13)
- (2024-11-13)
- (2024-11-13)
- (2024-11-13)
- (2024-11-13)
- (2024-11-12)
- (2024-11-12)
- (2024-11-12)
- (2024-11-12)
- (2024-11-12)
天演药业于2024 SITC年会上公布其抗 CTLA-4 SAFEbody® ADG126(Muzastotug)单一疗法及与抗 PD-1 疗法联用最新临床数据
(2024-11-12)- (2024-11-12)
- (2024-11-12)
百奥赛图宣布IDEAYA提名具有同类首创潜力的B7H3/PTK7双特异性ADC(IDE034)作为开发候选药物并行使选择权
(2024-11-12)- (2024-11-11)
- (2024-11-11)
- (2024-11-11)
- (2024-11-11)
- (2024-11-11)
- (2024-11-11)
- (2024-11-11)
- (2024-11-11)
- (2024-11-11)
- (2024-11-11)
- (2024-11-11)
- (2024-11-11)
- (2024-11-11)
Nature Aging:武汉大学伍兵团队揭示了年龄相关胸腺退化的机制——METTL3通过调控铁死亡影响胸腺细胞发育和胸腺退化
(2024-11-10)- (2024-11-10)
- (2024-11-10)
- (2024-11-10)
- (2024-11-10)
- (2024-11-10)
- (2024-11-10)
- (2024-11-10)
- (2024-11-09)
- (2024-11-09)
- (2024-11-09)
- (2024-11-09)
GUT:发现肝癌细胞“刺客”!上海东方肝胆外科医院团队首次揭示,肝癌细胞表达的质膜蛋白ADCY7能够招募T细胞,改善免疫抑制环境
(2024-11-09)- (2024-11-09)
- (2024-11-09)
- (2024-11-09)
- (2024-11-09)
- (2024-11-09)
- (2024-11-08)
- (2024-11-08)
- (2024-11-08)
- (2024-11-08)